Immunologic Factors: all 3,292 studies that test it
Page 21 of 33. Open to participants first (386), then studies with results posted, then the rest; newest registration first within each.
- Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory MyelomaWithdrawnNCT02986451Phase 2
- Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisPTerminatedNCT02983097Phase 1/2
- SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line ChemotherapyStatus unknownNCT02976740Phase 2
- PCD Versus RCD for the Treatment of Patients With Waldenstrom's MacroglobulinemiaStatus unknownNCT02971982Phase 1/2
- Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)Status unknownNCT02966717Phase 2
- Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02960646Phase 1
- A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)TerminatedNCT02957019Phase 1/2
- Intravenous Immunoglobulin in Prevention of Preterm Neonatal SepsisCompletedNCT02954926Phase 3
- Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 MutationCompletedNCT02950051Phase 3
- A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma PatientsCompletedNCT02945215Phase 1
- Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS SyndromeCompletedNCT02921893Early Phase 1
- A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell TransplantationCompletedNCT02918331Phase 1
- Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple MyelomaStatus unknownNCT02916420Phase 3
- A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's LymphomaTerminatedNCT02914938Phase 1
- Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in ChildrenWithdrawnNCT02899702Phase 4
- Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple MyelomaTerminatedNCT02897830Phase 2
- A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MMActive, not recruitingNCT02886065Phase 1
- Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified TreatmentCompletedNCT02881086Phase 3
- Study in End-stage Renal Disease Patients Awaiting Kidney Transplant to Investigate the Potential Effect of IVIG Treatment on the Pharmacokinetics and Pharmacodynamics of LFG316CompletedNCT02878616Phase 1
- Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell LymphomaStatus unknownNCT02871869Phase 2/3
- A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma PatientsCompletedNCT02867566Phase 3
- Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent LesionsStatus unknownNCT02867553Phase 3
- EDOCH Alternating With DHAP for New Diagnosed Younger MCLCompletedNCT02858804Phase 4
- Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic AnemiaCompletedNCT02845596Not applicable
- The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström MacroglobulinemiaCompletedNCT02844322Phase 4
- SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic StudyCompletedNCT02840708Phase 1
- Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine TumorsCompletedNCT02838342Phase 2
- Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in JapanCompletedNCT02835742Phase 2
- Rituximab, Eltrombopag and Dexamethasone as Frontline Treatment for Immune ThrombocytopeniaStatus unknownNCT02834286Phase 2
- Omental Islet TransplantCompletedNCT02821026Phase 1/2
- Rituximab in Eosinophilic Granulomatosis With PolyangiitisCompletedNCT02807103Phase 3
- Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,PanobinostatWithdrawnNCT02802163Phase 1/2
- Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and OverStatus unknownNCT02792491Phase 2
- Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease in Patients With Common Variable ImmunodeficiencyWithdrawnNCT02789397Phase 2
- Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic LeukemiaCompletedNCT02779283Phase 1
- Study of ACTR087 in Subjects With Relapsed or Refractory B-cell LymphomaCompletedNCT02776813Phase 1
- Methylprednisolone During the Switch Between Natalizumab and FingolimodStatus unknownNCT02769689Phase 4
- CyBeR Association in Relapsed/Refractory DLBCLStatus unknownNCT02758925Phase 2
- Treatment of ITP With Rituximab and / or AccutaneStatus unknownNCT02757196Phase 2
- Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell LymphomaStatus unknownNCT02753062Phase 2
- Reduced Chemotherapy in Low Risk DLBCLStatus unknownNCT02752815Phase 4
- An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell LymphomaCompletedNCT02752204Phase 2
- RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.CompletedNCT02746744Phase 3
- Clinical Trial to Evaluate Efficacy and Safety of Acellbia® (JSC "BIOCAD") With Methotrexate in First Line Biological Therapy of Patients With Active Rheumatoid ArthritisCompletedNCT02744196Phase 3
- A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell LymphomaWithdrawnNCT02735876Phase 3
- A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)Active, not recruitingNCT02734771Phase 2
- Rituximab (RTX) for Disease Modifying Anti Rheumatic Drug (DMARD) Non-responders in Pakistan: The Pakistan Rituximab Study (PARIS)CompletedNCT02731560Phase 4
- Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell LymphomaCompletedNCT02728531Phase 1
- A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)CompletedNCT02723071Phase 1/2
- A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)TerminatedNCT02720120Phase 1/2
- A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple MyelomaActive, not recruitingNCT02718833Phase 2
- Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly SchedulesCompletedNCT02711228Phase 4
- Allogeneic Stem Cell Transplantation for Children With CMLCompletedNCT02707393Phase 2/3
- Treatment of IgG4-Related Disease With Revlimid and RituximabCompletedNCT02705638Phase 1
- Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)WithdrawnNCT02702960Phase 2
- Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple MyelomaCompletedNCT02697344Phase 1
- A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid ArthritisCompletedNCT02693210Phase 2
- Ig PRx in AECOPD: Pilot StudyCompletedNCT02690038Phase 2
- Bendamustine and Rituximab Combination Therapy for Cold Agglutinin DiseaseCompletedNCT02689986Phase 2
- Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCLActive, not recruitingNCT02682641Phase 2
- Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCTCompletedNCT02677181Phase 4
- To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125CompletedNCT02673567Phase 1
- Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell LymphomaCompletedNCT02670616Phase 2
- Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's DiseaseWithdrawnNCT02667496Phase 2
- Allo HSCT Using RIC for Hematological DiseasesCompletedNCT02661035Phase 2
- Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi SarcomaActive, not recruitingNCT02659930Phase 1
- IVIg to Treat BK Viremia in Kidney Transplant RecipientsCompletedNCT02659891Phase 1
- Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple MyelomaActive, not recruitingNCT02659293Phase 3
- Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple MyelomaCompletedNCT02655458Phase 1
- Dose Study of Antithymocyteglobulin in Haploidentical Allogeneic Stem Cell TransplantationStatus unknownNCT02643589Not applicable
- Intravenous Immunoglobulin Therapy for Small Fiber NeuropathyCompletedNCT02637700Phase 2
- Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in RemissionActive, not recruitingNCT02632396Phase 1/2
- A Study to Evaluate Pain, Tolerability, Safety, and Usability of a Single Self-administered Etrolizumab by Auto-injector in Healthy ParticipantsCompletedNCT02629744Phase 1
- Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCTTerminatedNCT02627573Phase 2
- Rituximab for the Otolaryngologic Manifestations of Granulomatosis With PolyangiitisTerminatedNCT02626845Phase 4
- Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaWithdrawnNCT02623920Phase 2
- A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT02616640Phase 1
- Inhaled GM-CSF for Respiratory Virus-Associated Severe PneumoniaWithdrawnNCT02601365Phase 1
- Diabetes Islet Preservation Immune TreatmentWithdrawnNCT02586831Phase 1/2
- UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD CombinationWithdrawnNCT02578121Phase 2
- Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK CellsActive, not recruitingNCT02573896Phase 1
- Rituximab in Recurrent IgA NephropathyStatus unknownNCT02571842Phase 4
- HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple MyelomaCompletedNCT02569320Phase 1
- Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin LymphomaCompletedNCT02568553Phase 1
- Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia VasculitisTerminatedNCT02556866Phase 2
- Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN)CompletedNCT02556437Phase 2
- Intrathecal Rituximab in Progressive Multiple SclerosisCompletedNCT02545959Phase 2
- Trial of Immunomodulatory Therapy in High Risk Solitary Bone PlasmacytomaActive, not recruitingNCT02544308Phase 3
- Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple MyelomaActive, not recruitingNCT02542657Phase 1/2
- Lenalidomide Maintenance in Plasma Cell MyelomaActive, not recruitingNCT02538198Phase 2
- Immune Modulation Therapy for Pompe DiseaseStatus unknownNCT02525172Phase 4
- Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral SuspensionCompletedNCT02521714Phase 1
- Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous LeukemiaWithdrawnNCT02520102Phase 2
- Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate TransplantationCompletedNCT02513186Phase 1
- Minimal Islet Transplant at Diabetes OnsetCompletedNCT02505893Phase 2
- Allo-HSCT With Alternative Donor in Treatment of Hematologic MalignancyCompletedNCT02487069Not applicable
- Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic DisordersCompletedNCT02484053Early Phase 1
- Natalizumab in Inclusion Body Myositis (IBM)Status unknownNCT02483845Phase 1
- Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCTCompletedNCT02472691Phase 2
- Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma PatientsCompletedNCT02471820Phase 2